CORTRIA
Cortria Corporation is a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular and metabolic diseases. Cortria is based in Boston, MA.
The Company collaborates with leading clinics and academic institutions around the world.
The core activity of Cortria is investing in research and development. The company’s core value is caring for the health of patients by ensuring safety and the highest quality of our products.
TRIA-662
TRIA-662 (1-methylnicotinamide chloride, 1-MNA chloride) is a naturally occurring, major metabolite of nicotinic acid and a nicotinamide, two main forms of the B3 vitamin.
1-methylnicotinamide is produced endogenously by the metabolism of dietary nicotinamide. It is formed mainly in the liver by nicotinamide N-methyltransferase (NNMT).
1-MNA is then further metabolized to two pyridones. Both of these 1-MNA metabolites are excretion products.
Established a dominant IP position for both systemic and topical uses of 1-methylnicotinamide and owns the US IND and Canadian CTA regulatory filings.
DRUG DEVELOPMENT
Cortria is developing TRIA-662 for cardio-metabolic indications.
TRIA-662 has been investigated in phase I and in 14-week Randomized, Double-Blind, Placebo-Controlled, Forced Dose-Escalation, Multi-Center Study.
The well-tolerance and safety profile of TRIA-662 were confirmed in this study. In addition, TRIA-662 did not evoke the characteristic nicotinic acid adverse events of erythema and hot flush.
TRIA 662 is an interesting anti-inflammatory and metabolic modifying drug candidate. Pre-clinical and clinical studies demonstrate that TRIA-662:
• reduces inflammatory markers, hsCRP and TNF-alpha,
• stimulates production of prostacyclin (PGI2),
• improves vascular endothelial function,
• increases lipoprotein lipase activity,
• increases adiponectin level,
• reduces trigliceride (TG) blood level,
• extends lifespan in model of aging.
TRIA-662 may provide a potential new standard of care for the treatment of cardio-metabolic disorders.
The clinical results from Phase II study warrant further investigations for TRIA-662 in cardio-metabolic diseases:
• coronary artery disease,
• pulmonary arterial disease,
• non-alcoholic steatohepatitis,
• hypertriglyceridemia.